MM120, an LSD formulation designed to treat generalized anxiety disorder, was recently granted a breakthrough therapy designation by the FDA.
A single dose of an LSD formulation designed to treat generalized anxiety disorder can provide lasting relief within weeks, according to the biopharmaceutical company’s findings. MindMed, a psychedelic medicine biotech company, has been testing its MM120 – the salt form of lysergide, a hallucinogen commonly known as LSD.On Thursday, the company said the U.S. Food and Drug Administration had granted breakthrough therapy designation to its LSD formula for generalized anxiety disorder.
MM120 was "generally well-tolerated with most adverse events rated as mild to moderate, transient and occurring on dosing day, and being consistent with expected acute effects of the study drug," MindMed said in a release on the findings.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Single dose of LSD provides immediate and lasting relief from anxiety, study saysOne dose of LSD in a clinical trial significantly improved anxiety and lasted for 12 weeks, convincing the FDA to give the drug a breakthrough therapy designation.
続きを読む »
A new study with interesting results compared THC to the psychedelic drug LSD.A new study compared the neural effects of oral THC, the main active compound of cannabis, with a microdose of the classic psychedelic LSD.
続きを読む »
FDA Approves Wegovy For Heart Conditions in Game-Changing MoveThe Best in Science News and Amazing Breakthroughs
続きを読む »
FDA to Finally Outlaw Soda Ingredient Prohibited Around The WorldThe Best in Science News and Amazing Breakthroughs
続きを読む »
FDA approves Novo Nordisk's Wegovy for lowering heart risksThe Food and Drug Administration approved Novo Nordisk's weight-loss drug Wegovy on Friday for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
続きを読む »
FDA-Approved Tests for Genetic Mutations and CancerLearn about FDA-approved tests for genetic mutations and cancer, including BRCA1/2, Carrier Screen, GeneSight® Psychotropic, CDx, multi-gene panel, and Tumor test.
続きを読む »